Marco Maggi: ”Russian to the Bone" 20.01.2024
Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core. WHO interested in Russia's COVID-19 vaccine
/ Главная / Russkiy Mir Foundation / News / WHO interested in Russia's COVID-19 vaccineWHO interested in Russia's COVID-19 vaccine
06.07.2020
Photo credit: myseldon.com
The Russian COVID-19 vaccine is of interest in the World Health Organization (WHO), RIA Novosti reports. According to WHO Senior Researcher Soumya Swaminathan, the organization is monitoring the trial of avifavir.
Soumya Swaminathan recalled that WHO was implementing the Solidarity Tests program. Within its framework, countries exchange information on drugs and vaccines for coronavirus infection. Hopefully, the WHO spokeswoman added, Russia would join the program. So far, Moscow is not among the participants in the program, as are Beijing, London, Paris and Washington.
The trials of three prototype vaccines against the new coronavirus have been successfully completed. According to Rinat Maksyutov, head of the Vector Center for Virology and Biotechnology, these drugs can be called the best in terms of the results. The expert added that several groups were simultaneously creating new generation vaccines, about 100 people were ivolved in the work.
Russkiy Mir reported that two vaccines against coronavirus were to be registered by the Russian authorities in early autumn. According to Deputy Prime Minister Tatyana Golikova, the leaders in their development are the Gamalei Institute and the Vector center. The Gamalei Institute is working on a vaccine together with the 48th institute of the Russian defense department. They will conduct clinical trials in the summer. The developers suggest that the industrial production phase will begin in September.
Russkiy Mir